High‐grade B‐cell lymphomas with double or triple hits (MYC plus BCL2 and/or BCL6 genes rearrangements) (HGBL‐DH/TH) are usually highly aggressive lymphomas that respond poorly to conventional chemotherapeutic regimes [1]. This evidence concerns the gene BCL2 and B-cell non-Hodgkin lymphoma.